Abivax SA (ABVX) vs Belite Bio (BLTE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Belite Bio (BLTE) has outperformed Abivax SA (ABVX) over the past year, gaining 101.7% versus a gain of 0.0%. Abivax SA is the larger company by market cap ($7.59 billion vs $6.29 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVX | BLTE |
|---|---|---|
| Share price | $87.01 | $156.08 |
| Market cap | $7.59B | $6.29B |
| 1-day change | -1.37% | +0.30% |
| YTD return | -35.48% | -2.43% |
| 1-year return | 0.00% | +101.65% |
| Forward P/E | — | 69.06 |
| EPS (TTM) | $-6.00 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-77.61M |
| 52-week high | $148.83 | $200.00 |
| 52-week low | $69.81 | $76.50 |
| Distance from 52-week high | -41.54% | -21.96% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.48% | +46.65% |
| Average volume | 1.09M | 182.25K |
| Shares outstanding | 87.27M | 40.27M |
| Employees | 98 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed ABVX by 101.7 percentage points over the past year.
About Abivax SA
ABVX stock →ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
ABVX vs BLTE FAQ
Which is bigger, Abivax SA or Belite Bio?
Abivax SA (ABVX) is larger, with a market capitalization of $7.59B compared with $6.29B for Belite Bio (BLTE).
Which stock has performed better over the past year, ABVX or BLTE?
BLTE returned +101.65% over the past 12 months, compared with 0.00% for ABVX (price return, excluding dividends). Past performance does not predict future results.
Are Abivax SA and Belite Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.